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increasing inpatient utilization, the latter especially true for His-
panics. CONCLUSION: Although all veterans dramatically
adjusted pharmacy use following the copayment change, ethnic
minorities appeared particularly sensitive to drug costs. Similarly,
while white veterans appeared to reduce psychotropic use with
minimal consequences, minorities experienced substantially
elevated admission risks associated with lower cost-related
adherence. Beneﬁt changes for veterans with chronic conditions
should be implemented cautiously and carefully evaluated. Rec-
onciling budgetary concerns with quality care provision requires
sensitive attention to unique patient groups to ensure equity
while minimizing economic and health disparities.
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OBJECTIVE: To compare clinical characteristics of patients ini-
tiating treatment on duloxetine vs. those initiating on venlafaxine
XR, escitalopram, and ﬂuoxetine over a two year period.
METHODS: Retrospective claims analysis of Pharmetrics
managed care health plan patients initiating on select antidepres-
sants between September 1, 2004 and August 31, 2006. A total
of 798,259 patients were assigned to cohorts based on their most
recent antidepressant prescription. Cochran-Mantel-Haenszel
test was used to test the proportional differences among the
four cohorts. RESULTS: Overall, 72.1% of study patients were
female with a mean age of 44.3 years. Demographic differences
between cohorts were modest. Based on comparison of medical
claims within +/-30 days of initiation on venlafaxine XR, escit-
alopram, and ﬂuoxetine, respectively, duloxetine initiators were
more likely to have visited a mental health specialist (24.2% vs.
18.2%, 18.6%, and 16.5%) and been diagnosed with depression
(29.2% vs. 24.1%, 25.4%, 24.9%). Among the depressed,
duloxetine patients were more frequently diagnosed with major
depressive disorder (MDD) (52.8% vs. 44.3%, 40.5%, and
36.4%) and, among those diagnosed with MDD, were more
frequently diagnosed with recurrent MDD (78.2% vs. 73.8%,
66.2%, and 64.1%). Duloxetine initiators were more frequently
diagnosed with a pain condition (44.8% vs. 27.7%, 27.3%,
and 24.9%) , particularly for back (15.5% vs. 7.5%, 7.0%, and
6.3%) or musculoskeletal pain (28.2% vs. 15.5%, 14.4%. and
13.1%), and were more likely to have been treated previously
with a narcotic analgesic (24.2% vs. 11.1%, 9.8%, and 9.2%)
(p < 0.05 for all reported differences). CONCLUSION: Dulox-
etine patients are more likely to present with more severe depres-
sion diagnoses and pain than patients on other antidepressants.
Case mix adjustments should be made when comparing out-
comes and costs associated with treatment with different antide-
pressants. These ﬁndings are broadly consistent with earlier
analyses of data from the ﬁrst four months following introduc-
tion of duloxetine in the U.S.
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OBJECTIVE: To assess month-by-month changes in clinical
characteristics of patients initiating on duloxetine, a new anti-
depressant, during the ﬁrst two years following its initial avail-
ability in the United States. METHODS: Retrospective claims
analysis of Pharmetrics managed care health plan patients ini-
tiating on duloxetine between September 1, 2004 and August
31, 2006. A total of 102,567 duloxetine initiators were identi-
ﬁed for inclusion in this study. Monthly data series for demo-
graphic and clinical characteristics were created on the basis of
Cymbalta initiation date. Claims within +/-30 days of initiation
were used to identify clinical characteristics. RESULTS: Demo-
graphic patterns of patients initiating on duloxetine remained
stable over the two year period (average monthly percent female
73.0%; average monthly age 47.4 years), as did proportions of
patients with any anxiety (20.7%) or a GAD diagnosis (5.6%).
The average monthly % of patients treated by mental health
specialists trended downward over the ﬁrst 16 months of the
study period (from 32.3% to 23.7%), while the % with a
depression diagnosis trended downward (51.0% to 45.4%) for
the ﬁrst 12 months, before stabilizing thereafter. The % of
patients with a pain diagnosis increased over the ﬁrst three
months (62.4% to 66.6%) and remained stable thereafter. Of
those with a depression diagnosis, the % with an MDD diag-
nosis trended downward (55.8% to 45.8%) for 15 months
before stabilizing, while the % of those with MDD diagnosed
with Recurrent MDD remained stable over the entire study
period (77.8%). CONCLUSION: Demographic characteristics
of patients initiating on duloxetine in the two years following
initial availability in the United States have remained relatively
stable. Clinical characteristics have shown some variation, par-
ticularly over the ﬁrst 12 to 16 months following initial avail-
ability. These trends in utilization have implications for the
selection of appropriate methodologies for developing cohorts
for comparing utilization and costs between new and estab-
lished antidepressant medications.
WITHDRAWN PMH69
PMH70
AN INVESTIGATION OF EVIDENCE-BASED USE OF ATYPICAL
ANTIPSYCHOTICS IN ARKANSAS MEDICAID PEDIATRIC
Pathak P1,West D2, Martin BC2, Helm M2
1IMS Health, Falls Church,VA, USA, 2University of Arkansas for
Medical Sciences, Little Rock, AR, USA
OBJECTIVE: There has been a rapid increase in the use of
atypical antipsychotics in pediatric populations over the past few
years. Most of these drugs are unapproved in pediatric popula-
tions. Study objectives were: 1) To identify the trend of new users
of atypical antipsychotics in the Arkansas Medicaid population
under the age of 18 for years 2001 through 2005; 2) to classify
the use of each atypical antipsychotic as evidence-based or not
depending on the diagnoses for which it was prescribed; and 3) to
determine which pediatric patients are more likely to receive an
evidence-based atypical antipsychotic prescription. METHODS:
Study was a retrospective database analysis of Arkansas Medic-
aid for the period from January 2000 to December 2006. Par-
ticipants were the subjects under 18 years of age, with their ﬁrst
atypical antipsychotic prescription claim between 2001 and
2005, with no prior antipsychotic use and having a continuous
two-year Medicaid enrollment. Main outcome measure was the
proportion of study cohort with at least one evidence-based
atypical antipsychotic prescription claim, which was deﬁned as
any use of atypical antipsychotic supported by a clinical study in
the literature. RESULTS: The ﬁnal study cohort was 11,700. The
trend of new pediatric users of atypical antipsychotic therapy
increased from 1482 to 3110 new atypical users from 2001 to
2005. After identifying 86 clinical studies from the literature and
deﬁning the evidence-based use for each atypical antipsychotic, it
was found that 41.32% of the new pediatric users did not have
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